AI-accelerated discovery across oncology, immunology and metabolic diseases — from signal to candidate at unprecedented speed using MedGraphTM
0
Total Programs
0
Disease Areas
0
Pre-Clinical Stage
0
Clinical Stage
INDICATION
TARGET
TYPE
STAGE
Pan-Oncology
Breast, Prostate, Ovarian Cancer
Undisclosed*
NCE
PRE-DISCOVERYDISCOVERYPRE-CLINICALCLINICAL
⬡ Allosteric inhibition of conserved oncogenic signaling regulators
An AI-designed small-molecule program targeting conserved regulatory pockets in oncogenic signaling proteins. Leveraging Medvolt’s generative design, physics-based simulations, and ADMET optimization workflows, this program focuses on developing novel, selective inhibitors for multiple solid tumor subtypes.
Triple Negative Breast Cancer
TNBC
Undisclosed*
NCE
PRE-DISCOVERYDISCOVERYPRE-CLINICALCLINICAL
⬡ Synthetic lethality via DNA damage response pathway modulation
A rationally designed small-molecule program targeting DNA repair dependencies in TNBC. Using fragment-based and generative AI workflows, Medvolt is developing inhibitors that exploit replication stress and homologous recombination deficiencies to selectively impair tumor cell survival.
Acute Lymphoblastic Leukemia
ALL
Biologic / Enzyme
Asparagine Metabolism
PRE-DISCOVERYDISCOVERYPRE-CLINICALCLINICAL
⬡ Systemic depletion of extracellular asparagine via engineered enzyme variants
A next-generation enzyme therapeutic program focused on engineering optimized asparaginase variants with improved stability and reduced immunogenicity. The program integrates AI-guided protein design with experimental validation to enhance therapeutic efficacy in ALL and selected solid tumors.
Neurodegenerative Disorders
Parkinson’s, Alzheimer’s, ALS
Undisclosed*
NCE
PRE-DISCOVERYDISCOVERYPRE-CLINICALCLINICAL
⬡ Modulation of protein aggregation and neurodegenerative stress pathways
An exploratory small-molecule discovery program aimed at identifying novel modulators of protein misfolding, aggregation, and cellular stress pathways implicated in major neurodegenerative diseases, guided by AI-driven target prioritization and systems biology analysis.
Peptic Ulcer
Gastric & Duodenal Ulcers
Undisclosed*
RPE
PRE-DISCOVERYDISCOVERYPRE-CLINICALCLINICAL
⬡ Inhibition of Helicobacter pylori growth and ulcer progression pathways
A repurposed small-molecule program identified using Medvolt’s MedGraph platform, targeting Helicobacter pylori and associated ulcer pathology. The asset has completed preclinical validation and is positioned for potential out-licensing and partner-led clinical development.
NCE
New Chemical Entity
Novel small molecules designed or identified through Medvolt's AI-driven drug discovery platform.
RPE
Re-purposed Entity
Existing compounds repositioned for new indications using ML-identified mechanisms of action.
Enzyme Therapeutics
Asparagine Metabolism
AI-engineered enzyme therapeutics targeting asparagine metabolism for improved stability and reduced immunogenicity.
STRATEGIC PARTNERSHIPS
Interested in Partnering?
We're selectively engaging strategic partners and investors. Reach out to access our full pipeline brief and target disclosures under CDA.
Pipeline information is current as of Q1 2026 and subject to change without notice. * Full target disclosure available upon execution of a Confidentiality Disclosure Agreement (CDA).
Why Medvolt
Accelerate Discovery
Medvolt's AI-powered platform cuts pre-clinical discovery time by 3x, reduces costs by 15x and lowers failure risk by 25%. Enhance your R&D efficiency with our in silico tools.
High-Throughput Data
Enrich your research with Medvolt's proprietary, gold-standard, high-throughput proprietary datasets. Our AI and NLP solutions deliver speed, precision and scalability.
Expert Collaboration
Our experienced, tech-driven team collaborates globally with leading pharma and biotech companies, ensuring impactful, scalable solutions.
